Selected novel anticancer treatments targeting cell signaling proteins

被引:55
作者
Elsayed, YA [1 ]
Sausville, EA [1 ]
机构
[1] NCI, Dev Therapeut Program, Div Canc Treatment & Diagnosis, NIH,Clin Trials Unit, Rockville, MD 20852 USA
关键词
cell cycle; cyclin-dependent kinase; tyrosine kinase inhibitor; chemotherapy; histone deacetylase inhibitor; proteasome inhibitor;
D O I
10.1634/theoncologist.6-6-517
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Empirical approaches to discovery of anticancer drugs and cancer treatment have made limited progress in the cure of cancer in the last several decades. Recent advances in technology and expanded knowledge of the molecular basis of tumorigenesis and metastasis have provided unique opportunities to design novel compounds that rationally target the abnormal molecular and biochemical signals leading to cancer. Several such novel agents have completed advanced stages in clinical development. The excellent clinical results achieved by some of these compounds are creating new paradigms in management of patients with neoplastic diseases. Clinical development of these agents also raises challenges to the traditional methods of drug evaluation and measurement of efficacy.
引用
收藏
页码:517 / 537
页数:21
相关论文
共 191 条
[21]  
Busby EC, 2000, CANCER RES, V60, P2108
[22]   Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells [J].
Byrd, JC ;
Shinn, C ;
Ravi, R ;
Willis, CR ;
Waselenko, JK ;
Flinn, IW ;
Dawson, NA ;
Grever, MR .
BLOOD, 1999, 94 (04) :1401-1408
[23]   RATES OF P16(MTS1) MUTATIONS IN PRIMARY TUMORS WITH 9P LOSS [J].
CAIRNS, P ;
MAO, L ;
MERLO, A ;
LEE, DJ ;
SCHWAB, D ;
EBY, Y ;
TOKINO, K ;
VANDERRIET, P ;
BLAUGRUND, JE ;
SIDRANSKY, D .
SCIENCE, 1994, 265 (5170) :415-416
[24]  
Carlson B, 1999, CANCER RES, V59, P4634
[25]  
Carlson BA, 1996, CANCER RES, V56, P2973
[26]   Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer [J].
Catzavelos, C ;
Bhatacharya, N ;
Ung, YC ;
Wilson, JA ;
Roncari, L ;
Sandhu, C ;
Shaw, P ;
Yeger, H ;
MoravaProtzner, I ;
Kapusta, L ;
Franssen, E ;
Pritchard, KI ;
Slingerland, JM .
NATURE MEDICINE, 1997, 3 (02) :227-230
[27]  
Catzavelos C, 1999, CANCER RES, V59, P684
[28]   In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer [J].
Chien, M ;
Astumian, M ;
Liebowitz, D ;
Rinker-Schaeffer, C ;
Stadler, WM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (01) :81-87
[29]  
Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
[30]  
CORDONCARDO C, 1995, AM J PATHOL, V147, P545